All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-WJ0023 | Anti-ATP2B4 (CBWJC-0372) h(41BB-CD3ζ) CAR, pCDCAR1 | CBWJC-0372 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | |||
CAR-WJ2315 | Anti-ATP2B4 (CBWJC-0372) h(CD28-CD3ζ) CAR, pCDCAR1 | CBWJC-0372 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | |||
CAR-0320ZP295 | Anti-ATP2B4 (2G8) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2G8 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP296 | Anti-ATP2B4 (2G8) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2G8 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP297 | Anti-ATP2B4 (JA9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | JA9 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP298 | Anti-ATP2B4 (JA9) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | JA9 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP299 | Anti-ATP2B4 (CBYC-A875) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | CBYC-A875 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP300 | Anti-ATP2B4 (CBYC-A875) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | CBYC-A875 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP301 | Anti-ATP2B4 (2C7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 2C7 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-0320ZP302 | Anti-ATP2B4 (2C7) h(4-1BB-CD3ζ) CAR, pCDCAR1 | Human | 2C7 | Mouse | scFv-4-1BB-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION